Abstract
BackgroundImmunotherapy is a promising route towards personalized cancer treatment. A key algorithmic challenge in this process is to decide if a given peptide (neoepitope) binds with the major histocompatibility complex (MHC). This is an active area of research and there are many MHC binding prediction algorithms that can predict the MHC binding affinity for a given peptide to a high degree of accuracy. However, most of the state-of-the-art approaches make use of complicated training and model selection procedures, are restricted to peptides of a certain length and/or rely on heuristics.ResultsWe put forward USMPep, a simple recurrent neural network that reaches state-of-the-art approaches on MHC class I binding prediction with a single, generic architecture and even a single set of hyperparameters both on IEDB benchmark datasets and on the very recent HPV dataset. Moreover, the algorithm is competitive for a single model trained from scratch, while ensembling multiple regressors and language model pretraining can still slightly improve the performance. The direct application of the approach to MHC class II binding prediction shows a solid performance despite of limited training data.ConclusionsWe demonstrate that competitive performance in MHC binding affinity prediction can be reached with a standard architecture and training procedure without relying on any heuristics.
Highlights
Immunotherapy is a promising route towards personalized cancer treatment
We demonstrate that competitive performance in major histocompatibility complex (MHC) binding affinity prediction can be reached with a standard architecture and training procedure without relying on any heuristics
The results section is organized as follows: In “MHC class I binding prediction” section, we present a detailed evaluation of the performance of USMPep for MHC class I binding affinity prediction
Summary
Immunotherapy is a promising route towards personalized cancer treatment. A key algorithmic challenge in this process is to decide if a given peptide (neoepitope) binds with the major histocompatibility complex (MHC). This is an active area of research and there are many MHC binding prediction algorithms that can predict the MHC binding affinity for a given peptide to a high degree of accuracy. Immunotherapy is a promising route towards personalized cancer treatment with a variety of possible realizations, see [1,2,3,4] for recent reviews. The prediction if a MHC molecule binds to certain peptide is a very challenging task that is, a crucial sub task for neoantigen identification for practical realizations of personalized immunotherapy [1]
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.